a subsidiary of Lantheus Holdings, announced an agreement to acquire Evergreen Theragnostics for $250 million upfront and potential milestone payments of up to $752.5 million. This acquisition ...

Lantheus (LNTH) announced a definitive agreement to acquire Evergreen Theragnostics in an all-cash transaction consisting of an upfront payment of $250M and up to an additional $752.5M in ...

Lantheus (LNTH) announced a definitive agreement to acquire Evergreen Theragnostics in an all-cash transaction consisting of an upfront payment of $250M and up to an additional $752.5M in ...

Lantheus Holdings is stepping up its game in the radiopharmaceutical space by acquiring Massachusetts-based Evergreen Theragnostics for $250 million upfront. As part of the deal, which was announced ...

Prostate imaging drug Pylarify has become the first radiodiagnostic blockbuster, achieving over $1 billion in sales for 2024. The addressable market continues to expand.

Lantheus, a Massachusetts-based developer of radiopharmaceuticals, has agreed to acquire the radiopharma contract development and manufacturing organization (CDMO) Evergreen Theragnostics.

Lantheus Holdings (NasdaqGM:LNTH) saw an 18.83% increase in its share price over the past week, driven by recent corporate updates and market trends. The company announced its 2024 earnings, reporting ...

Evergreen Theragnostics. Lantheus will make an upfront payment of $250m, with the potential for an additional $752.5m in milestone payments. This marks Lantheus’ fifth acquisition since January ...

Brian Markison, CEO Evergreen Theragnostics is expected to add Octevy, a registrational stage PET radiodiagnostic that would complement Lantheus' therapeutic candidate, PNT2003. Both acquisitions ...